uniQure N.V. (NASDAQ:QURE) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on uniQure, with 13 buys, three holds and one sell among 17 analysts. The average 12-month price target is $65, although recent targets range from $28 to $80.
• QURE shares opened at $48.68, having traded between $8.73 and $71.50 over the past year. The company reported a quarterly loss of $1.22 per share, missing estimates, while revenue of $5.84 million exceeded expectations.
• Insiders sold approximately $16.8 million of stock over the last 90 days, including sales by the CEO and a director under pre-arranged trading plans. Institutional investors own approximately 78.83% of uniQure’s shares.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $65.00.

A number of research firms have recently weighed in on QURE. Leerink Partners increased their target price on shares of uniQure from $36.00 to $70.00 and gave the company an "outperform" rating in a research report on Thursday, June 18th. HC Wainwright lifted their price target on shares of uniQure from $50.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Weiss Ratings reiterated a "sell (e+)" rating on shares of uniQure in a research note on Friday, June 26th. Royal Bank Of Canada increased their price objective on uniQure from $35.00 to $65.00 and gave the company an "outperform" rating in a report on Thursday, June 18th. Finally, Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th.

uniQure Stock Down 0.1%

Shares of NASDAQ:QURE opened at $48.68 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The business's 50 day simple moving average is $44.52 and its two-hundred day simple moving average is $29.73. The firm has a market cap of $3.38 billion, a P/E ratio of -12.14 and a beta of 0.92.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business posted ($0.69) earnings per share. As a group, research analysts forecast that uniQure will post -3.74 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 21,167 shares of the firm's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares of the company's stock, valued at $1,207,254.24. This trade represents a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of uniQure stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares of the company's stock, valued at $23,448,291.32. The trade was a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 388,229 shares of company stock valued at $16,817,099. 4.65% of the stock is currently owned by insiders.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. Seven Fleet Capital Management LP purchased a new stake in uniQure during the second quarter valued at about $15,254. Arizona State Retirement System boosted its holdings in shares of uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company's stock worth $267,000 after purchasing an additional 627 shares in the last quarter. Ensign Peak Advisors Inc increased its position in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock valued at $87,000 after purchasing an additional 650 shares during the last quarter. CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the 3rd quarter valued at about $50,000. Finally, IFP Advisors Inc purchased a new position in shares of uniQure during the 4th quarter valued at about $48,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source